On October 26, 2017, we highlighted INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) as being a turnaround stock in the biotechnology space.
At the time, the company was trading in and around $0.30 a share having spent the two or three weeks prior to our coverage declining and we said that – at its then-current price – shares looked cheap ahead of a potential long-term recovery.
Fast forward to today, November 13, and it looks as though we were right on the money.
At market open this morning, the company will kick off the session at $0.55 a share – a close to 85% run on the price at which we highlighted the stock.
So what’s next?
In short, we expect big things from this company and, in line with that, further appreciation in value going forward. Of course, we have to back this up with something, so why do we think there’s value in an Inmed exposure right now?
READ FULL STORY AT INSIDER FINANCIAL